A recent report by the Manila Times highlighted Madrigal Pharmaceuticals’ unveiling of a series of new analyses and real-world findings supporting the therapeutic profile of resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis (MASH), to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona.
The upcoming presentations underscore the growing clinical evidence base for resmetirom across multiple dimensions of MASH management, extending beyond traditional liver endpoints to include cardiovascular risk and portal hypertension.
Cardiometabolic Benefits Gain Attention
Among the highlights is a secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 studies, focusing on biomarkers linked to cardiovascular risk. Investigators report improvements in key lipid parameters, including lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB). These findings are particularly relevant given the high burden of cardiovascular disease in patients with MASH, suggesting that resmetirom may provide dual metabolic and hepatic benefits.
Insights into Portal Hypertension in Cirrhosis
Additional data evaluate outcomes in patients with compensated MASH cirrhosis (fibrosis stage F4c), drawing on two-year follow-up results. Analysis using the ANTICIPATE-NASH risk score—an emerging noninvasive tool for estimating clinically significant portal hypertension—indicates potential improvement in risk stratification metrics among treated patients. This may point to a broader role for resmetirom in modifying complications associated with advanced liver disease.
Real-World Evidence and Noninvasive Monitoring
Complementing clinical trial findings, Madrigal will also present early real-world evidence reflecting routine clinical use of resmetirom. These data aim to validate trial outcomes in broader patient populations and clinical settings.
In parallel, several abstracts examine the performance of noninvasive biomarkers in predicting fibrosis improvement in patients with moderate-to-advanced disease (F2–F3) and compensated cirrhosis. Such tools could help clinicians monitor therapeutic response more effectively without relying on liver biopsy.
Expanding the Role of Resmetirom
According to company leadership, the collective findings reinforce the position of resmetirom as a foundational therapy in MASH. The data reflect a more comprehensive understanding of treatment impact, encompassing liver health, systemic metabolic risk, and disease progression markers.
As the field continues to evolve, these insights presented at EASL 2026 highlight an increasing focus on integrated disease management and the importance of noninvasive approaches in both clinical trials and everyday care.
